Validation of a flow cytometric competitive efflux assay for assessing clinically important drugs as canine P-glycoprotein substrates
American Journal of Veterinary Research · 2026
DOI: 10.2460/ajvr.25.11.0419 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift American Journal of Veterinary Research, 2026. Verfasst von Neal S Burke und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily B, Member 1, Flow Cytometry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Because dogs with P-glycoprotein (P-gp) deficiency experience enhanced susceptibility to adverse reactions caused by P-gp substrate drugs, this study’s purpose was to validate and employ a competitive efflux assay to assess clinically relevant drugs as P-gp substrates.
Methods
A competitive efflux assay employing a cell line expressing canine P-gp was used in these studies. Intracellular fluorescence was detected flow cytometrically following the coincubation of experimental drugs with 2 intrinsically fluorescent P-gp substrates (rhodamine 123 or calcein AM) that bind different sites within the P-gp binding pocket. The fluorescence intensity was determined for cells treated with each experimental drug and fluorescent P-gp substrate combination and compared to the fluorescence intensity of cells treated with rhodamine 123 and calcein AM alone. Additionally, assay validation parameters were assessed.
Results
Mean fluorescence intensity (MFI) ratios < 2 indicate non–P-gp substrates [cisplatin (negative control), ropinirole, doxycycline, and trilostane]; MFI ratios from 2 to 5 indicate weak canine P-gp substrates (apomorphine, capromorelin, and enrofloxacin); MFI ratios > 5 but < 10 indicate moderate P-gp substrates (trazodone); and MFI ratios > 10 indicate strong P-gp substrates [loperamide (positive control), and moxidectin]. Assay specificity, precision, and linearity were within established acceptance criteria.
Conclusions
Several clinically relevant drugs were identified as P-gp substrates. The competitive efflux assay is a useful tool for screening drugs as canine P-gp substrates. Clinical Relevance These results imply that P-gp–deficient dogs may be at increased risk of adverse effects if treated with apomorphine, capromorelin, enrofloxacin, or moxidectin, depending on the dose administered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Katrina L Mealey
Zitieren
APA
Burke, N. S., & Mealey, K. L. (2026). Validation of a flow cytometric competitive efflux assay for assessing clinically important drugs as canine P-glycoprotein substrates. American Journal of Veterinary Research. https://doi.org/10.2460/ajvr.25.11.0419
Vancouver
Burke NS, Mealey KL. Validation of a flow cytometric competitive efflux assay for assessing clinically important drugs as canine P-glycoprotein substrates. American Journal of Veterinary Research. 2026. doi:10.2460/ajvr.25.11.0419
BibTeX
@article{Burke2026,
author = {Burke, Neal S and Mealey, Katrina L},
title = {Validation of a flow cytometric competitive efflux assay for assessing clinically important drugs as canine P-glycoprotein substrates},
journal = {American Journal of Veterinary Research},
year = {2026},
doi = {10.2460/ajvr.25.11.0419}
}
EUVIMED